Skip to main content

What the FDA labels say about taking them together

Methocarbamol and pyridostigmine

Methocarbamol's FDA label of March 17, 2026 names pyridostigmine in its drug interactions section; the pyridostigmine labels PlainMeds reads (4) do not name methocarbamol.

Check it at the source: the methocarbamol FDA label on DailyMed (effective March 17, 2026, Oxford Pharmaceuticals, LLC); the pyridostigmine FDA label on DailyMed (effective December 2, 2020, Bausch Health US, LLC).

What does the methocarbamol label say about pyridostigmine?

Methocarbamol label, drug interactions

Methocarbamol may inhibit the effect of pyridostigmine bromide.

Source: FDA drug label (Atmeksi, NDA219843), Rosemont Pharmaceuticals LLC, effective March 13, 2026 (SPL set 62de7345-613b-4838-96e5-aceca3cea6b2), via openFDA

Source: FDA drug label (Methocarbamol), Oxford Pharmaceuticals, LLC, effective March 17, 2026 (SPL set 06dc72a6-ef3a-425a-9194-a9d228093cc4), via openFDA; the full label on DailyMed

What does the pyridostigmine label say about methocarbamol?

Pyridostigmine's label (effective December 2, 2020) and its 3 other brand-application labels do not name methocarbamol in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Mestinon), Bausch Health US, LLC, effective December 2, 2020 (SPL set a851795e-b7a8-40c3-9922-5e79d3eb4d92), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

65Methocarbamol generic labelers
16Pyridostigmine generic labelers
MethocarbamolPyridostigmine
Labeled forMuscle spasms and spasticityn/a
Boxed warningNoNo
Pharmacy cost (NADAC)$0.0395 per tablet 500 mg tablet$0.249 per tablet 60 mg tablet
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?